Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Clinical Psychopharmacology

• Publication date

  2005-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00004850-200503000-00001PMID 15729080
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Depressing research.

  2004cited by this paper
• Depressing research.

  2004cited by this paper
• Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

  2003cited by this paper
• Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses

  2003cited by this paper
• The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

  2003cited by this paper
• Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.

  2003cited by this paper
• The economic burden of depression in the United States: how did it change between 1990 and 2000?

  2003cited by this paper
• Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study

  2003influential reference
• A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.

  2003cited by this paper
• A randomized, double‐blind, 24‐week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care

  2003cited by this paper
• Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.

  2002influential reference
• Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.

  2002cited by this paper
• Prevalence of sexual dysfunction among newer antidepressants.

  2002cited by this paper
• Current methods of the US Preventive Services Task Force: a review of the process.

  2001cited by this paper
• Meta-analytical studies on new antidepressants.

  2001influential reference
• A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.

  2001cited by this paper
• Systematic Reviews in Health Care

  2001cited by this paper
• The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia

  2000cited by this paper
• Efficacy of newer medications for treating depression in primary care patients.

  2000cited by this paper
• Mirtazapine compared with paroxetine in major depression.

  2000influential reference
• Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.

  2000cited by this paper
• A Systematic Review of Newer Pharmacotherapies for Depression in Adults: Evidence Report Summary: Clinical Guideline, Part 2

  2000influential reference
• Indirect comparison in evaluating relative efficacy illustrated by antimicrobial prophylaxis in colorectal surgery.

  2000cited by this paper
• Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.

  2000cited by this paper
• A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.

  1999cited by this paper
• Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.

  1999cited by this paper
• Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment

  1999cited by this paper
• A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.

  1999cited by this paper
• Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression

  1998influential reference
• Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.

  1998cited by this paper
• Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.

  1998cited by this paper
• A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.

  1997cited by this paper
• A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.

  1997cited by this paper
• Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.

  1997cited by this paper
• Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.

  1996cited by this paper
• Definition and epidemiology of treatment-resistant depression.

  1996cited by this paper
• A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.

  1996cited by this paper
• Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

  1995cited by this paper
• Selective serotonin reuptake inhibitors: meta‐analysis of discontinuation rates

  1994cited by this paper
• Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.

  1993cited by this paper
• Double-blind comparison of bupropion and fluoxetine in depressed outpatients.

  1991cited by this paper

• The role of natural products and traditional Chinese medicine formulas in postpartum depression: mechanism and prospects

  2025cites this paper
• Choline Alphoscerate: A Therapeutic Option for the Management of Subthreshold Depression in the Older Population

  2025cites this paper
• Probiotics and the Gut–Brain Axis: Emerging Therapeutic Strategies for Epilepsy and Depression Comorbidity

  2025cites this paper
• Feasibility and Clinical Effects of Accelerated Sequential Bilateral Theta Burst Stimulation in Late-Life Depression (ACCELDER Trial)

  2025cites this paper
• Estimation of the benefit from pre‐emptive genotyping based on the nationwide cohort data in South Korea

  2024cites this paper
• Effect of probiotic administration to breastfeeding mothers with very low birthweight neonates on some neonatal and maternal outcomes: study protocol for a randomised, double-blind, placebo-controlled trial

  2024cites this paper
• Trazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability

  2023influential citation
• The feasibility of acupuncture as an adjunct intervention for antenatal depression: a pragmatic randomised controlled trial.

  2020cites this paper
• How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations

  2020cites this paper
• The Gut-Brain-Axis on the Manifestation of Depressive Symptoms in Epilepsy: An Evidence-Driven Hypothesis

  2020cites this paper
• Retention rates of antiepileptic drugs in glioma patients: the most appropriate outcome

  2020cites this paper
• Meta-analysis of placebo group dropout in adult antidepressant trials.

  2019cites this paper
• Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports

  2019cites this paper
• Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient

  2017cites this paper
• The effects of probiotics on depressive symptoms in humans: a systematic review

  2017cites this paper
• Effect of Lactobacillus rhamnosus HN001 in Pregnancy on Postpartum Symptoms of Depression and Anxiety: A Randomised Double-blind Placebo-controlled Trial

  2017cites this paper
• Selective Serotonin Reuptake Inhibitors as First‐Line Antidepressant Therapy for Perinatal Depression Symbol

  2017cites this paper
• Guidance by physicians and pharmacists during antidepressant therapy: patients’ needs and suggestions for improvement

  2017cites this paper
• Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment.

  2016cites this paper
• The Effectiveness of Stress Management Programme on Depression , Stress , and Anxiety of Depressed Patients

  2016cites this paper
• Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline

  2016cites this paper
• Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder

  2016cites this paper
• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

  2015cites this paper
• Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

  2014influential citation
• Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.

  2014cites this paper
• Common SSRI side-effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: Data from a randomized controlled trial

  2014cites this paper
• Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

  2014influential citation
• Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder

  2014influential citation
• Efficacy, tolerability, and acceptability of bupropion for major depressive disorder: a meta-analysis of randomized–controlled trials comparison with venlafaxine

  2013cites this paper
• Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial.

  2013cites this paper
• Routledge Handbook of Physical Activity and Mental Health

  2013cites this paper
• Peer Reviewed Title: Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: A randomized controlled trial

  2013cites this paper
• Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.

  2012cites this paper
• Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies.

  2012cites this paper
• A review of preliminary observations on agomelatine in the treatment of anxiety disorders.

  2012cites this paper
• Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice?

  2012cites this paper
• CHAPTER 8 – Cognition in the aging adult

  2012cites this paper
• Depression in adults: drug and physical treatments.

  2011cites this paper
• Time to discontinuation among the three second‐generation antidepressants in a naturalistic outpatient setting of depression

  2011cites this paper
• Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder

  2010cites this paper
• Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression

  2010cites this paper
• A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV.

  2010cites this paper
• Differences in clinical effect and tolerance between fluvoxamine and paroxetine: A switching study in patients with depression

  2010cites this paper
• Profile of Adverse Events with Duloxetine Treatment

  2010cites this paper
• Discontinuation rates in clinical trials in musculoskeletal pain: meta-analysis from etoricoxib clinical trial reports

  2008cites this paper
• Psychiatric and psychological factors in patient decision making concerning antidepressant use.

  2008cites this paper
• Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants.

  2008cites this paper
• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines

  2008cites this paper
• Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: systematic review and meta-analysis.

  2008cites this paper
• Selective Serotonin Reuptake Inhibitor Discontinuation: Side Effects and Other Factors That Influence Medication Adherence

  2007cites this paper
• INTERVENTIONS INTERVENTIONS IN MILD TO MODERATE, OR SE- VERE DEPRESSION

  2007cites this paper
• Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials*

  2007cites this paper
• Depression in adults: drug and physical treatments.

  2007cites this paper
• Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis.

  2007cites this paper
• Paroxetine: current status in psychiatry

  2007cites this paper
• Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion

  2007cites this paper
• Limitations of current medical treatments for depression: disturbed circadian rhythms as a possible therapeutic target.

  2007cites this paper
• Emergency care in the first 48 hours

  2007cites this paper
• Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities

  2006cites this paper
• The drug effectiveness review project: an important step forward.

  2006cites this paper
• Bupropion: pharmacology and therapeutic applications

  2006cites this paper
• Current awareness in human psychopharmacology.

  2005cites this paper
• Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder

  2005cites this paper
• Priority medicines for Europe and the world

  2004cites this paper
• Pharmacology Mini-Review

  year unknowncites this paper